Phase 2 N=320 A Study of NGM621 in Participants With Geographic Atrophy
Geographic Atrophy
Primary: The Rate of Change From Baseline in Geographic Atrophy (GA) Lesion Area — 2.243; 2.237; 2.393 mm^2 per year — p=0.4345
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=180 Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events
Cardiovascular Diseases · Atherosclerosis · Lipoprotein(a)
Primary: Time-averaged Percent Change In Lipoprotein(a) Molar Concentration From Baseline to Week 36 — -80.5; -79.1; -83.3; 2.3 Percentage — p=<0.0001
Phase 2 N=206 Study of Safety and Tolerability of CFZ533 in Patients With Sjögren's Syndrome
Sjogren's Syndrome
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 0; 0; 127; 43 Participants
Phase 2 N=22 VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1
HIV Infections
Primary: Monotherapy: Maximum Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) — -1.17; -2.15; -2.31; -0.28 Copies per milliliter…
Phase 2 N=42 Temozolomide Chronotherapy for High Grade Glioma
Glioma · Glioblastoma Multiforme
Primary: Feasibility of Patient Treatment Compliance as Measured by Number of Participants Who Were at Least 80% Compliance With Assigned Administration Time — 17; 15 Participants
Phase 2 N=92 A Study of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines
Glabellar Lines
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 7; 15; 9; 2 Participants
Phase 2 N=50 Exenatide Once-weekly as a Treatment for Multiple System Atrophy
Multiple System Atrophy
Primary: Change in UMSARS Score (Parts I+II) From Baseline — 6.1; 13.3 score on a scale
Phase 2 N=141 Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX)
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Primary: Two Years Overall Survival (OS) — 24.7; 13.4 percentage of participants
Phase 2 N=82 Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)
Nonalcoholic Steatohepatitis (NASH)
Primary: Change in Absolute Liver Fat Content (Part 1) — -9.68; -11.91; -0.85 percent of liver fat — p=<0.001
Phase 2 N=70 Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement
Recurrent Plasma Cell Myeloma · Refractory Plasma Cell Myeloma
Primary: The Primary Objective of the Study is to Test Whether the NFKB2 Rearrangement Can Guide the Selection of Treatment (Ixazomib Plus Dexamethasone (Id) or Ixazomib Plus…
Phase 2 N=37 Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation
Acute Myeloid Leukemia · Acute Myelogenous Leukemia · Myelodysplastic Syndrome
Primary: Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 16; 31; 39; 46 Participants
Phase 2 N=319 Efficacy, Safety, and PK of LX9211 in Participants With Diabetic Peripheral Neuropathic Pain
Diabetic Peripheral Neuropathy · Diabetes
Primary: Change From Baseline to Week 6 in ADPS as Measured by the Numerical Rating Scale — -0.72; -1.39; -1.27 score on a scale — p=0.007
Phase 2 N=15 COVID Protection After Transplant - Sanofi GSK (CPAT-SG) Study
COVID-19 · Kidney Transplant
Primary: The Proportion of Participants Who Reach a SARS-CoV-2 S Antibody Level >5000 U/mL — 0 Participants
Phase 2 N=6 Pozelimab and Cemdisiran Combination Therapy in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Switch From Eculizumab Therapy
Paroxysmal Nocturnal Hemoglobinuria
Primary: OLTP: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 6 Participants
Phase 2 N=274 A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy
Acute Pain
Primary: Time-Weighted Sum of Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) 0 to 48 Hours (SPID48) After the First Dose of Study Drug…